GlassScriptPhysician profile
Ostap Dovirak
NPI 1912141417
$3,699.26
in general payments reported to CMS, 2019-2025
35 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $67.60 · 2023: $95.57 · 2024: $1,100 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,031 · Travel and Lodging: $44.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,030.93 |
| Travel and Lodging | $44.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $504.09 | 2019-2025 | Axonics, Ams 700, Lithovue |
| Procept Biorobotics Corporation | $396.38 | 2024-2025 | Aquabeam System |
| Baxter Healthcare | $309.32 | 2024-2025 | Tisseel |
| Teleflex LLC | $285.59 | 2023-2025 | Urolift |
| Srs Medical Systems, INC. | $234.23 | 2024 | Ct3000 Pro Base Unit, Urocuff-Dc Disposable, Single |
| Axonics, INC. | $210.61 | 2024 | Axonics, Bulkamid |
| Astellas Pharma US INC | $178.55 | 2019 | |
| Valencia Technologies Corporation | $175.83 | 2025 | Ecoin Device Kit |
| Neotract INC. | $160.38 | 2019 | |
| Sumitomo Pharma America, INC. | $138.76 | 2024-2025 | Orgovyx |
| Koelis INC. | $135.83 | 2025 | |
| Laborie Medical Technologies Corp. | $118.37 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Janssen Pharmaceuticals, INC | $103.79 | 2025 | Erleada |
| Pfizer INC. | $70.11 | 2019-2025 | |
| Janssen Biotech, INC. | $69.94 | 2019-2025 | Erleada |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $69.35 | 2019 | |
| Olympus America INC. | $49.04 | 2019-2024 | Itind System |
| Dendreon Pharmaceuticals LLC | $46.44 | 2024-2025 | Provenge |
| Endo USA, INC. | $40.27 | 2024-2025 | Xiaflex |
| Agiliti Surgical, INC. | $39.03 | 2025 | Boston Scientific Lumenis Pulse 120h Holmium Laser W/ Moses Technology, Koelis Trinity Mri/US Fusion, Sonablate Hifu |
| Antares Pharma, INC. | $37.40 | 2024 | Xyosted |
| Abbvie INC. | $33.24 | 2024 | |
| Novartis Pharmaceuticals Corporation | $33.21 | 2025 | |
| Tempus Ai, INC | $29.02 | 2025 | Xt Cdx |
| Edap Technomed INC | $26.42 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $25.34 | 2025 | Lynparza |
| Convatec INC. | $25.12 | 2024 | |
| Myriad Genetic Laboratories, INC. | $24.70 | 2024 | Prolaris |
| Blue Earth Diagnostics | $24.00 | 2019 | |
| Urogen Pharma, INC. | $22.94 | 2024 | |
| Verity Pharmaceuticals INC. | $21.10 | 2025 | Tlando |
| Coloplast Corp | $17.30 | 2024 | |
| Endo Pharmaceuticals INC. | $16.29 | 2019 | |
| Rochester Medical Corporation | $15.29 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ostap Dovirak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.